Survival improvements associated with access to biological agents: Results from the South Australian (SA) metastatic colorectal cancer (mCRC) registry.
about
Randomized study comparing full dose monotherapy (S-1 followed by irinotecan) and reduced dose combination therapy (S-1/oxaliplatin followed by S-1/irinotecan) as initial therapy for older patients with metastatic colorectal cancer: NORDIC 9.Bevacizumab in Colorectal Cancer: Current Role in Treatment and the Potential of Biosimilars.Age-related systemic treatment and survival of patients with metachronous metastases from colorectal cancer.
P2860
Survival improvements associated with access to biological agents: Results from the South Australian (SA) metastatic colorectal cancer (mCRC) registry.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh
2016年學術文章
@zh-hant
name
Survival improvements associat ...... rectal cancer (mCRC) registry.
@en
Survival improvements associat ...... ults from the South Australian
@nl
type
label
Survival improvements associat ...... rectal cancer (mCRC) registry.
@en
Survival improvements associat ...... ults from the South Australian
@nl
prefLabel
Survival improvements associat ...... rectal cancer (mCRC) registry.
@en
Survival improvements associat ...... ults from the South Australian
@nl
P2093
P2860
P1433
P1476
Survival improvements associat ...... orectal cancer (mCRC) registry
@en
P2093
Amanda R Townsend
Amitesh C Roy
Carol Beeke
Rob Padbury
Shahid Ullah
Timothy J Price
Yoko Tomita
P2860
P304
P356
10.3109/0284186X.2015.1117135
P577
2016-02-15T00:00:00Z